Treatment Approach to Type 2 Diabetes: Past, Present and Future
From the desk of Kumari Suninda
In India, 77 million people (about twice the population of California) above the age of 18 have diabetes (Type 2) and an estimated 25 million have pre-diabetes (high risk of diabetes soon). More than 50% are unaware of their diabetes, a condition that causes health complications that occur if not diagnosed and treated promptly. Adults with diabetes are two to three times more likely to develop heart disease and stroke. Combined with decreased blood flow, vascular disease (nerve damage) in the foot increases the need for foot ulcers, infections, and eventual amputations. Diabetes mellitus cataracts are a leading cause of blindness, damage to small blood vessels accumulated over time in the eyes. Diabetes is one of the main causes of kidney failure.
Diabetes mellitus (DM) is a chronic, progressive metabolic disorder throughout life characterized by hyperglycemia due to absolute or hypoinsulinemia. There are many forms of DM and each result from a complex interaction between genetic predisposition and environmental factors. Metabolic dysregulation that contributes to hyperglycemia includes insulin resistance, impaired glucose utilization or increased glucose production, ultimately leading to pathophysiological changes in many organs and organ systems.
Type 2 diabetes mellitus (DM) is a lifelong metabolic disorder, characterized by progressive hyperglycemia and progressive neurological complications. It is recognized as a global burden disease, as it has a significant impact on human health (mortality) and health care costs. Between insulin secretion and insulin resistance interaction complex evolving from the previously known “bad triangle virate” to the “bad six.” The pharmacological approach has evolved from biguanides to a wide range of drugs that appear to exert positive effects on the cardiovascular system.
View more info and detailed Table of Contents here: https://www.skyquestt.com/report/type-2-diabetes-market
Is Diabetes Curable?
There is currently no cure for diabetes, but the disease can progressively be controlled with good diet, regular exercise, and periodic medical checkups. When diabetes goes into remission, it means that the body no longer shows symptoms of diabetes, although technically the disease is still present. Clinicians have yet to reach a final consensus on what constitutes true remission, but all have included a 6.5% lower A1C level as an important factor. The A1C level represents a person’s blood sugar over a 3-month period.
Medications
While lifestyle adjustments can help reduce the impact of type 2 diabetes, most people with this condition will need to take medications lower blood glucose and boost the body’s production of and sensitivity to insulin.
These includes following drug classes:
-
Glucagon-like peptide-1 (GLP-1) agonists: Glucagon-like peptide-1 agonists are a class of drugs used to treat type 2 diabetes and obesity. This session will focus on the indications, mechanism of action, administration, side effects, and contraindications for these drugs. The use of multidisciplinary teams of nurses, primary care providers, physicians, and neurologists remains relevant to the care of patients prescribed this class of drugs. These stimulate the body to produce insulin and suppress glucagon production by the pancreas when blood sugar levels are high. Among others, dulaglutide is a common GLP-1 antagonist for diabetics.
-
Alpha-glucosidase inhibitors: Alpha-glucosidase inhibitors (AGIs) are a class of drugs used to treat type 2 diabetes alone or in combination with other antidiabetic drugs. They can also be used in patients with poor glucose tolerance and may cause diabetes a second delayed in these patients. They are particularly useful for patients at risk for hypoglycemia or lactic acidosis, and as such are not suitable for use with other antidiabetic agents such as sulfonylureas and metformin. These prevent the breakdown of starch and help lower blood glucose levels. People should include them in their first meal. Acarbose and miglitol are common alpha-glucosidase inhibitors for diabetics.
Revolutionizing Diabetes Care: Unveiling the AI Powered Future
The first AI-based medical device, Body Guardian, has been launched by the US. It was recognized by the Food and Drug Administration (FDA) in 2012 when it authorized regulations of a patch-like electrocardiogram enhanced with an AI-based arrhythmia detection algorithm incorporating programmed medical devices. The number of AI-based medical devices approved in the US. and Europe have grown significantly in the last few years due to notable advances in deep learning technologies and recent advances in clinical applications.
There are now dozens of FDA-cleared AI-based medical devices that use AI/machine learning technology. While most of these approvals relate to radiology, cardiology, and oncology, three AI-based medical devices relate to diabetes management. Japan has approved 12 AI-based medical devices by 2020. However, all of them are for radiology and diagnostic imaging, and no such medical devices have been approved for diabetes care.
Role of Diabetes Cure in Hemodynamic Monitoring Systems Market:
Hemodynamic monitoring requires assessment of circulatory blood flow, which is important for managing medical conditions related to diabetes. costs. Treatment of diabetes can impact the hemodynamic monitoring system market by cardiovascular complications a about diabetes which can reduce. Improved cardiovascular health can lead to changes in critical surveillance systems.
Role of Diabetes Cure in IoT Healthcare Market:
The Internet of Things (IoT) in healthcare connect medical devices and systems to collect and exchange data, enabling real-time monitoring and monitoring of patient health. Treating diabetes could lead to IoT-enabled devices for continuous glucose monitoring, insulin delivery and diabetes. The information generated by these IoT devices can be used to better understand patient health, improve treatment planning and improve overall quality of care.
Role of Diabetes Cure in 4D Printing in Healthcare Market:
4D Printing Market size was valued at USD 126.82 million in 2022 and is poised to grow from USD 178.7 million in 2022 to USD 2777.56 million by 2030, growing at a CAGR of 40.91% in the forecast period (2024-2031). 4D printing is about producing dynamic materials, which change shape over time. It has the potential to revolutionize drug delivery, neurotechnology and generalized medicine in healthcare. If diabetes treatment becomes more effective, 4D printing could play a role in intelligent drug delivery systems. These systems can address the dynamic health status of a patient, releasing insulin or essential medications as needed.
Conclusion:
As we stand at the intersection of innovation and healthcare, the mixing of 4D printing, IoT, and hemodynamic monitoring structures gives a promising trajectory towards a treatment for diabetes. These technologies not only address the immediately demanding situations of glycemic manipulate and3w customized method to diabetes care. With ongoing studies and collaboration, the confluence of those modern-day technologies holds the potential to convert the lives of those laid low with diabetes and propel us closer to a future without this chronic condition.
Find the Author at: Linkedin
Related Reports:
USA (+1) 351-333-4748
